Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 103 cases, liver metastases were found in 40 at autopsy. Of these, 34 could be further evaluated. In 15, the metastases had been demonstrated by scintigraphy. Six patients were not examined because of the rapid course of the disease, and in a further two diffuse metastases in the liver were not recognised. Of the patients in whom metastases had been missed, in eight the deposits were less than 1 cm, in another eight they were between 1 and 2 cm and, in the remaining three patients, they were between 2 and 3 cm. The findings are discussed in detail. False positive or inconclusive findings were obtained in two patients (3.2%). All thirteen cases with cirrhosis of the liver were correctly diagnosed. In four patients abnormalities of the liver parenchyma were incorrectly diagnosed (false positive). Patients with fatty livers were diagnosed equally as normal or as having parenchymal damage.
 ...
PMID:[Liver scintigraphy. A comparison between scintigraphic and autopsy findings (author's transl)]. 645 5

An assay for the estimation of guanosine deaminase is described. The method employs guanosine as substrate and after incubation of serum and substrate at 22 degrees C for 18 h the ammonia liberated is estimated using the Berthelot reaction. Absorbance is measured as 625 nm and the catalytic activity read from a standard curve obtained using ammonia standards. The method provides reproducible measurements of serum guanosine deaminase. The results obtained using 'normal' sera have been used to calculate the 'normal range' for the enzyme in serum. Preliminary results suggest that guanosine deaminase is increased in hepatitis and in patients with liver metastases but normal in all other liver diseases including cirrhosis and obstructive jaundice.
 ...
PMID:The estimation of serum guanosine deaminase activity in liver disease. 666 43

Twenty-two postmortem specimens of the liver (18 normal livers, three with liver metastases, and one with liver cirrhosis) with attached ligamenta teres were investigated using silicone rubber injection technique. In all cases, the paraumbilical veins were demonstrated. They were usually divided into 2 groups, one on the right and one on the left side of the ligamentum teres, and they terminated in a variable manner into small peripheral portal vein branches in the liver parenchyma. A patent segment of the umbilical vein was found in 7 of the 22 cases. Connections between the umbilical vein and paraumbilical veins were supposed to represent one of the collateral channels in portal hypertension.
 ...
PMID:Umbilical and paraumbilical veins in ligamentum teres. Their significance as collaterals in portal hypertension. 673 Oct 5

The lack of a worldwide-accepted classification of liver metastases makes it difficult to compare data on natural history and results from different treatments. The increasing interest in aggressive multimodal therapies for hepatic metastases prompted us to review the chief prognostic factors and the main published classifications in order to propose a new clinical classification, whose principal application concerns metastases from colorectal adenocarcinomas. Following the general rules of the TNM classification, liver metastases are classified by expressing with letters and numbers the parameters selected for their prognostic importance, clinical applicability and objectivity. H (hepatic) is the letter that indicates the liver is the site of metastasis. Synchronous metastases are indicated by H, metachronous by rH (r = recurrent). The extent of liver involvement is defined: H1, liver involvement less than 25%; H2, from 25 to 50%; H3, more than 50%. Site of metastases is defined by s (single), m (multiple to one surgical lobe), b (to both lobes), i (infiltration of important structures). The alteration of liver functions is indicated by F. The presence of cirrhosis is noted by C.
 ...
PMID:Proposal for a clinical classification of liver metastases. 717 97

We determined the serum molybdenum concentration by neutron activation analysis in apparently healthy subjects and in patients with diseases of the liver and biliary system. The level was found to be markedly elevated in the initial phase of acute viral hepatitis (mean +/- S.D. 3.10 +/- 1.46 ng/ml vs. 0.55 +/- 0.21 in controls) and to return to normal during convalescence, in parallel with the liver function tests. The most significant correlations were found between the serum molybdenum concentration and the serum levels of GOT ( r = 0.710, p less than 0.001) and GPT (r = 0.683, p less than 0.001). Besides, the serum molybdenum level (mean +/- S.D.) was observed to be definitely increased in patients with HBsAg-positive chronic active hepatitis (0.97 +/- 0.49 ng/ml), HBsAg-positive liver cirrhosis (1.01 +/- 0.50), alcoholic liver disease (1.32 +/- 0.56), liver metastases (1.40 +/-0.39), gallstones (1.28 +/- 0.38), tumors of the gallbladder or extrahepatic bile ducts (1.64 +/- 0.44), and carcinoma of the head of the pancreas (1.61 +/- 0.91). Finally, the serum molybdenum level was found to be raised in two patients with primary biliary cirrhosis and in two out of four patients with drug-induced liver injury. The etiologic mechanism and the clinical importance of the observed abnormality remain to be established. Our study enlarges the existing information concerning the disorders of trace element metabolism in liver diseases.
 ...
PMID:Serum molybdenum in diseases of the liver and biliary system. 720 61

Serum levels of sIgA were quantitated by a new radioimmunoassay in patients with a variety of diseases, lactating women and clinically healthy blood donors. Significantly elevated levels compared to controls were found in lactating women, patients with Crohn's disease and patients with cirrhosis, but not in patients with rheumatoid arthritis, IgA myeloma or neoplastic disease. Patients with inflammatory disease and serum IgA levels at least two-fold greater than the normal mean and patients with a variety of other diseases did not show elevated levels of sIgA. In the two latter groups, patients with hepatic disease were excluded. High levels of sIgA were found in four patients with liver metastases from extrahepatic neoplasms. The results indicate that the liver is important for the maintenance of normal serum levels of sIgA.
 ...
PMID:Reassessment of levels of secretory IgA in pathological sera using a quantitative radioimmunoassay. 728 96

Fifteen repeat hepatic resections were performed on 12 patients with either recurrent or residual malignant tumours of the liver. Of these, one patient underwent three repeat resections and another underwent two. Five had primary liver liver tumours and seven had liver metastases. Planned, 'staged', repeat resections were performed on three patients because of multiple deposits of tumour, cirrhosis or extensive disease at initial presentation. There was no operative mortality. The period of follow-up from the time of repeat sections ranged between 4 months and 36 months during which two patients died from recurrent disease. The mean survival after the repeat resection was 16.8 months (range 4-36 months). Although technically demanding, repeat hepatectomy is feasible and provide similar benefits.
 ...
PMID:Repeated resection for malignant liver tumours. 748 64

Haemorrhage from oesophageal varices is a common and potentially life-threatening complication of portal hypertension, which is usually due to cirrhosis of the liver. Although liver metastases and hepatic dysfunction frequently occur in malignant disease, reports of oesophageal varices arising as a consequence of metastatic liver disease are sporadic, suggesting that this complication is unusual. Indeed, one review of the literature identified only 23 cases, although a few others have subsequently been reported. The management of such patients bleeding from oesophageal varices is clearly very different from bleeding due to other causes such as peptic ulceration. We report three cases and review the literature. All of our cases presented to us within a period of one year, suggesting that this complication of metastatic liver disease is more common than originally considered to be the case.
 ...
PMID:Oesophageal varices: a potentially fatal complication of liver metastases. 772 Aug 99

A variety of diffuse and focal disease processes affect the liver. MRI is likely the imaging modality of choice for investigation of patients suspected of having diffuse disease such as cirrhosis, hemochromatosis, or fatty infiltration. MRI is extremely effective at detecting and characterizing focal hepatic lesions. In particular, patients suspected of possessing hemangiomas, hepatocellular carcinoma, or hypervascular liver metastases are better evaluated by MRI than other imaging modalities. Immediate post gadolinium spoiled gradient echo and T2-weighted fat suppressed spin echo are very effective at lesion detection, whereas serial post gadolinium spoiled gradient echo is essential for lesion characterization. New fast T2-weighted sequences and tissue specific contrast agents may further increase the role of liver MRI by shortening exam time and increasing sensitivity and specificity, respectively.
 ...
PMID:Magnetic resonance imaging of the liver. 777 72

We evaluated levels of insulin-like growth factor-I and interleukin-1 alpha and beta in patients with pancreatic cancer; the role of these substances in tumor spread and in hyperglycemia was also investigated. Thirty pancreatic cancer patients (21 with hyperglycemia) were compared with others with diseases causing hyperglycemia [liver cirrhosis (14 cases, 12 with hyperglycemia), chronic pancreatitis (20 cases, 12 with hyperglycemia), type I diabetes mellitus (13 cases, all hyperglycemic)]. Insulin-like growth factor-I was significantly reduced in patients with liver cirrhosis, probably due to a reduced hepatic capacity for synthesis. It was increased in 6 of 30 pancreatic cancer patients; in these subjects it was correlated with alanine aminotransferase and C-peptide, but not with tumor diameter or the presence of metastases. Interleukin-1 alpha and beta were both elevated in pancreatic cancer patients. The former was high, while the latter was low when liver metastases were present. Neither was related to glucose or C-peptide levels. In summary, insulin-like growth factor-I levels are increased in some pancreatic cancer patients but this does not seem to favor tumor spread; however IGF-I could be involved influencing glucose homeostasis. Interleukin-1 alpha increased, while interleukin-1 beta decreased in pancreatic cancer patients with metastases, suggesting a different involvement of these two substances in pancreatic cancer spread.
 ...
PMID:Insulin-like growth factor-I, interleukin-1 alpha and beta in pancreatic cancer: role in tumor invasiveness and associated diabetes. 778 9


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>